Abstract
Background: Triple-negative breast cancer (TNBC) accounts for 15–20% of all invasive breast cancer (BC) and is frequently associated with adverse prognosis. Pathologic complete response (pCR) has been associated with improved survival in early-stage BC. While anthracycline and taxane-based neoadjuvant chemotherapy (NCT) remains the standard of care, addition of platinum seems to increase pCR rate, with no significant difference in survival. Objectives of this study are to review clinical decisions regarding NCT and to evaluate the pCR rate in TNBC patients (pts) in our centre.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
